Skip to main content
Premium Trial:

Request an Annual Quote

Signature Dx to Manage CRC Clinical Trials in Germany for OncoMethylome

NEW YORK (GenomeWeb News) – OncoMethylome Sciences said Tuesday it has contracted the German company Signature Diagnostics to help it manage the German component of its multi-center clinical trials for a colorectal cancer diagnostic.
 
Under the agreement, OncoMethylome also has acquired a minority interest in Potsdam-based Signature Diagnostics, and it will give the company an up-front payment as well as service fees. Additional financial terms of the agreement were not disclosed.
 
The deal also gives OncoMethylome first negotiation rights on a test Signature Diagnostics is developing to predict colorectal cancer patient outcomes.
 
"Signature Diagnostics demonstrated that it is able to support a large, multi-center, prospective clinical trial in colorectal cancer with its trial technology,” OncoMethylome CEO Herman Spolders said in a statement.
 
Liege, Belgium-based OncoMethylome is focused on developing tests for detecting cancer in its early stages, predicting patient response to therapeutics, and predicting the chance of cancer recurrence.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.